Dr. Hamilton joined MAPS in 2015 as a statistical consultant. He has been deeply involved in the analysis of the Phase 2 studies of MDMA-assisted psychotherapy for PTSD. He designed the statistical aspects of the current pivotal studies. He was formerly President and Founder of DynaRand, LLC, a software company that pioneered the development of IVRS and IWRS solutions for clinical trials management. DynaRand was acquired by United BioSource Corporation in 2005. Since the inception of DynaRand in 1998, he has pioneered the use of IXRS for automated adaptive studies, especially in the area of dynamic randomization. Dr. Hamilton has an Adjunct Professor appointment at Stanford University's School of Medicine in the Department of Neurology and Neurological Sciences, where he has been the primary statistician on multiple acute stroke studies. Dr. Hamilton sits on several data safety monitoring committees and works closely with pharmaceutical companies regarding the statistical aspects of adaptive trials and randomization algorithms. Previously, Dr. Hamilton was a statistical reviewer for the NI-NINDS Grant Review Committee. Widely published, he holds memberships in the American Statistical Association and the American Stroke Association. Dr. Hamilton received his undergraduate degree from the University of California at Davis, his Master of Science from the University of California at Los Angeles in Biostatistics, and his Ph.D. in Biostatistics from the University of North Carolina. He is passionate about his family, and enjoys biking, camping, and singing.